Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Food and Drug Administration as a weight loss management treatment for people with obesity or those who are overweight with at least one related underlying condition such as high blood pressure
The FDA signaled escalating enforcement, and on April 30, 2026, it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list - the mechanism that governs which substances large-scale compounders may use - with a public comment period open through June 29, 2026
They might give you a prescription to help
The difference between FDA-approved GLP-1s and compounded GLP-1s Glucagon-like peptide-1 (GLP-1) medications are prescribed to treat and manage Type 2 diabetes and obesity
US$ 20.75
US$ 20.77
US$ 28.56
US$ 25.80
US$ 26.02
US$ 23.94
US$ 24.56
US$ 29.65
US$ 23.75
US$ 21.97
US$ 24.15
